[1] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline:management of adult patients with ascites due to cirrhosis 2012. Hepatology,2013,57（4）:1651-1653.
[2] 王宇明. 肝硬化合并低钠血症-顽固性腹水-急性肾损伤的防治新认识. 中华肝脏病杂志,2012,20（7）:481-486.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南.实用肝脏病杂志,2013,16（3）：210-216.
[4] Torres VE,Chapman AB,Devuyst O,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med,2012,367（25）:2407-2418.
[5] Okita K,Kawazoe S,Hasebe C,et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema:A randomized,double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:83-91.
[6] Sakaida I,Kawazoe S,Kajimura K,et al. Tolvaptan for improvement of hepatic edema: A phase 3,multicenter,randomized,double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:73-82.
[7] Gines P,Angeli P,Lenz K,et al.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）: 397-417.
[8] 王宇明. 重症感染的临床诊治进展. 第三军医大学学报, 2011,33（21）:2219-2222.
[9] Lontos S,Shelton E,Angus PW,et al. A randomised controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis,2014,15（5）:260-267.
[10] Lee YY,Tee HP,Mahadeva S.Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. World J Gastroenterol,2014,20（7）:1790-1796.
[11] Quinlan GJ,Martin GS,Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology,2005,41（6）:1211-1219.
[12] Garcia-Martinez R,Caraceni P,Bernardi M,et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology,2013,58（5）:1836-1846.
[13] Maitland K,Pamba A,English M,et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria:preliminary evidence of albumin benefit. Clin Infect Dis, 2005,40（4）:538-545.
[14] Chen TA,Tsao YC,Chen A,et al. Effect of intravenous albumin on endotoxin removal,cytokines,and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol,2009,44（5）:619-625.
[15] Fernandez J,Monteagudo J,Bargallo X,et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology,2005,42（3）:627-634.
[16] Salerno F,Navickis RJ,Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis:a meta-analysis of randomized trials. Clin Gastroenterol Hepatol,2013,11（2）:123-130. |
